NanoViricides to Showcase Revolutionary Antiviral Drug at LSX Congress

NanoViricides, Inc., a clinical-stage developer of antiviral drugs, is set to present at the LSX World Congress 2025 in Boston on September 17th. The presentation by Dr. Anil R. Diwan, President and Executive Chairman, will update participants on the company's drug pipeline, including NV-387, an advanced broad-spectrum antiviral candidate.

NV-387 targets respiratory viruses and is touted as a breakthrough comparable to antibiotics' impact on bacterial infections. The drug disrupts virus particles, preventing infection and overcoming virus evolution challenges seen with vaccines and small molecules.

Additionally, NV-387 is advancing towards a Phase II evaluation for MPOX treatment. NanoViricides is also developing NV-HHV-1, an anti-herpesvirus drug, and NV-HIV-1 for HIV.